Fatigue interleukin

Aldesleukin is a recombinant form of human Interleukin-2 (IL-2). It has been approved for the treatment of malignant melanoma and renal cell cancer. The medicine is administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Adverse reactions include hypo- and hypertension, gastrointestinal disturbances, fever, fatigue, lethargy, joint pain, headache. Cardiovascular problems may occur. 

The most common side effects of interleukin-11 are fatigue, headache, dizziness, and cardiovascular effects. The cardiovascular effects include anemia (due to hemodilution), dyspnea (due to fluid accumulation in the lungs), and transient atrial arrhythmias. Hypokalemia has also been seen in some patients. All of these adverse effects appear to be reversible. In the limited clinical trial data available thus far, recombinant thrombopoietin appears to be well tolerated. 

Of 52 patients with colorectal cancer treated with a median of six 3-weekly cycles of raltitrexed 1.5-3.0 mg/m combined with oral carmofur 300-400 mg/m on cycle days 2-14, 39 had a fever on days 2-9 after receiving raltitrexed, 49 had fatigue, and 49 had a raised serum C-reactive protein concentration without a documented infection (6). Median concentrations of C-reactive protein, interleukin-6, interleukm-8, and tumor necrosis factor-alfa were higher 7 days after raltitrexed or raltitrexed + carmofur than at baseline. The authors suggested that patients with colorectal cancer treated with raltitrexed may develop drug-related systemic inflammation, which may be difficult to distinguish from infection. 

Monoclonal antibody therapy rituximab, alemtuzumab Non-specific immunotherapies and adjuvants BCG, interleukin-2 (IL-2), and interferon-a Immunomodulating drugs thalidomide and lenalidomide Cancer vaccines vaccine for advanced prostate cancer Side effects Flu-like symptoms, including fever, chills, nausea, and loss of appetite, allergic reactions, fatigue decrease in blood pressure Work better for some types of cancer than for others... 

---